Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Trial Profile

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ATTAIN
  • Sponsors Biogen
  • Most Recent Events

    • 19 Jun 2018 Results of subgroup analysis of ADVANCE/ATTAIN presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of a subgroup analysis from ADVANCE, ATTAIN, TEMSO and TOWER studies comparing the clinical outcomes of peginterferon beta-1a and teriflunomide in DMT niave RMS patients, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results comparing the efficacy of subcutaneous (SC) peginterferon beta-1a and oral teriflunomide in patients from four randomised trials (ADVANCE, ATTAIN, TEMSO and TOWER), presented at the 69th Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top